"riociguat" as the first treatment
For pulmonary hypertension, Consultant Chest Diseases and President of the Saudi Society for Pulmonary Hypertension, Dr. Magdy Muhammad Idris, confirmed that the Saudi Food and Drug Authority has approved Riociguat as the first drug for treating patients with chronic obstructive pulmonary hypertension that cannot be treated surgically, or Which patient recurs or persists after surgery.
The drug has also been approved for the treatment of 3 pulmonary arterial hypertension, which is another type of pulmonary hypertension, thus becoming the only drug approved for the treatment of two types of pulmonary hypertension.
He pointed out that chronic obstructive pulmonary hypertension and pulmonary arterial hypertension are considered rare types of pulmonary hypertension, which is a serious disease that affects the lungs and heart and develops to change the patient’s life and threatens him with death as well, and it is estimated that obstructive pulmonary hypertension Chronic thrombotic affects 1500-2000 people in the Kingdom, while pulmonary arterial hypertension affects 1000-1500 people, as patients develop high blood pressure in the lung arteries, which causes them to have difficulty breathing and severe fatigue and hinders their ability to work and practice daily activities such as walking short distances Or climbing stairs.
The President of the Saudi Society for Pulmonary Hypertension revealed the results of the important clinical study «CHEST-1» which showed that Riosiguat is the first and only drug that has achieved significant clinical improvement for patients with chronic obstructive pulmonary hypertension that cannot be treated surgically or that the patient is recurring. Do or continue after surgery. Riociguat improved patients'' ability to endure exercise, which was demonstrated by evaluating a six-minute walking test, revealing an improvement in their ability to walk a longer distance.
This came during the scientific and introductory symposium on the drug that was held yesterday, Saturday, at the Jeddah Hilton Hotel, which included many scientific lectures presented by professors and specialists from various countries of the world who dealt with introducing the drug and its side effects, in addition to its therapeutic effect on patients suffering from pulmonary artery hypertension. Chronic and the extent of the therapeutic benefits of this drug.
